Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update Conference Call to be Held Monday

Atossa Genetics Announces Second Quarter

2016 Financial Results

and Provides Company Update

Conference Call to be Held Monday August

15, 2016 at 4:30 pm Eastern Time

SEATTLE, August 12, 2016 -- Atossa Genetics Inc. (NASDAQ:

ATOS) today announced Second Quarter ended June 30, 2016 financial results and provided an update on recent company developments.

Dr. Steve Quay, President and CEO, commented, "We are

encouraged by our continued progress on both our recently announced new drug development program with oral endoxifen, and our ongoing

Phase 2 clinical trial of intraductal fulvestrant administration in women with ductal carcinoma in situ (DCIS) or invasive breast

cancer." Dr. Quay continued, "With our recently announced settlement with Besins Healthcare, we will have an additional

$1.76 million to commit to executing on the promise of our two exciting drug developments programs. We have made substantial progress

on both of our drug development programs: For oral endoxifen we have filed patent applications; contracted for the initial drug

supply; and identified its initial indication -- breast cancer patients who are refractory to tamoxifen thereby getting little

or no benefit from taking tamoxifen. Our Phase 2 clinical trial of intraductal fulvestrant is ongoing and is progressing as planned."

Recent Corporate Developments

Atossa's important recent

developments include the following:

Q2 2016 Financial Results

Total operating expenses were $1.7 million and $4.0 million

for the three months and six months ended June 30, 2016, respectively, consisting of general and administrative (G&A) expenses

of $1.6 million and $3.7 million, respectively, and R&D expenses of $169,000 and $319,000, respectively. As a result of the

sale of NRLBH in December 2015, operating expenses related to the NRLBH are presented separately as discontinued operations for

the three months and six months ended June 30, 2015.

Operating expenses from continuing operations for the three

months and six months ended June 30, 2016 decreased $1.5 million and $2.4 million, or 45.7% and 37.1%, respectively, from $3.2

million and $6.4 million for the three months and six months ended June 30, 2015, respectively, which consisted of G&A expenses

of $2.4 million and $4.8 million, respectively, R&D expenses of $373,000 and $939,000, respectively, and selling expenses of

$343,000 and $689,000, respectively. The decrease in operating expenses is mainly attributed to the 2015 launch of new devices

and services which are not being pursued in 2016 and investing more in new R&D programs in the first quarter of 2015 compared

For the three months and six months ended June 30, 2016, the

Company recorded a net loss of $1.7 million and $4.0 million, respectively.

Conference Call Information

Management will host a business update conference call on Monday

August 15, 2016 at 4:30 pm eastern time to review Second Quarter ended June 30, 2016 financial results and provide a company update.

Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the

U.S. should call 1-844-824-3830 and

International callers should call 1-412-317-5140. All callers

should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com.

Details for the webcast may be found on the Company's IR events page at http://ir.atossagenetics.com/ir-calendar.

A replay of the call will be available approximately one hour

after the end of the call through September 15, 2016. The replay can be accessed via Atossa's website or by dialing 877-344-7529

(domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10091229.

About Atossa Genetics

Atossa Genetics Inc., is developing novel and locally-administered

pharmaceuticals to address breast conditions, including cancer. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa

undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from

the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the

FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results

of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations

and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights,

and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation

its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.

CFO and General Counsel

Investor Relations Contact

Garden City, NY 11530

Office: 516.222.2560

Source: Atossa Genetics Inc.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS